Background-Essential hypertension has been recognized as a disease resulting from a combination of environmental and genetic factors. Recent studies demonstrated that microRNAs (miRNAs) are involved in cardiac hypertrophy and heart failure. However, little is known about the roles of miRNAs in essential hypertension. Methods and Results-Using microarray-based miRNA expression profiling, we compared the miRNA expressions in plasma samples from 13 hypertensive patients and 5 healthy control subjects. Twenty-seven miRNAs were found to be differentially expressed. The expressions of selected miRNAs (miR-296 -5p, let-7e, and a human cytomegalovirus [HCMV]-encoded miRNA, hcmv-miR-UL112) were validated independently in plasma samples from 24 hypertensive patients and 22 control subjects. The absolute expression levels of hcmv-miR-UL112, miR-296 -5p, and let-7e were further determined in 127 patients and 67 control subjects (fold changes are 2.5, 0. 
specific treatment. Vascular inflammation and endothelial dysfunction have been implicated in the pathogenesis of hypertension via adhesion molecules, chemokine expression, and nitric oxide synthase dysfunction. [3] [4] [5] [6] Clinical Perspective on p 184 microRNAs (miRNAs) are short, endogenous, noncoding RNAs that regulate gene expression at the posttranscriptional level by binding to the 3Ј untranslated regions (UTRs) of their target mRNAs. 7 Although dysregulation of miRNA expression is a feature of malignancies, 8 -10 research into miRNAs in biological processes reveals their regulation of immune cell development, 11 involvement in inflammatory response, 12 and critical participation in cardiac hypertrophy and heart failure pathogenesis. 13, 14 miRNAs are stable in plasma and serum and may be suitable as blood-based biomarkers in different cancers and other diseases. 15, 16 In this study, we demonstrate the expression pattern of miRNAs in the plasma of patients with essential hypertension. We found hcmv-miR-UL112, a human cytomegalovirus (HCMV)-encoded miRNA, is highly expressed in hypertensive patients compared with control subjects. A ubiquitous DNA virus of the Herpesviridae family, HCMV replicates only in humans. 17 It has been implicated in several cardiovascular disorders, including atherosclerosis, coronary heart disease, and cardiac transplant arteriopathy. 18 -20 Some studies suggest an association between HCMV and cardiovascular disorders through impaired endothelial nitric oxide synthase function 21, 22 and subsequent endothelial dysfunction, 23, 24 resulting in reduced vascular dilation in vivo. However, direct links between HCMV infection, endothelial dysfunction, and essential hypertension remain undefined. Therefore, the aims of the present study were to determine the plasma miRNA expression pattern of patients with essential hypertension and to determine the association and potential relationships among HCMV, hcmv-miR-UL112, and essential hypertension.
Methods

Study Population
The study protocol was approved by the Medical Ethics Committee of the Chaoyang Hospital of Capital Medical University, and informed consent was obtained from each subject. The microarray cohort included 13 hypertensive patients and 5 healthy control subjects; the second validation cohort was composed of 24 hypertensive patients and 22 healthy control subjects; and the third validation cohort was composed of 194 hypertensive patients and 97 healthy volunteers (a detailed description can be found in the Methods and Materials section in the online-only Data Supplement).
Plasma Collection and RNA Isolation
Whole blood (10 mL) was drawn into EDTA-containing tubes and separated into plasma and cellular fractions by centrifugation at 1000g for 10 minutes. Total plasma RNA was harvested with the TRI Reagent BD (Sigma Aldrich, St. Louis, MO) and the RNeasy mini kit (Qiagen, Valencia, CA) according to the manufacturers' instructions. In detail, 250 L EDTA-containing plasma was transferred to an Eppendorf tube and mixed thoroughly with TRI Reagent, incubated for 5 minutes at room temperature, and subsequently mixed with 140 L chloroform. The aqueous phase containing the RNA was carefully removed, and RNA was precipitated by addition of 100% ethanol. The mixture was applied to an RNeasy Mini spin column and washed several times, and RNA was eluted by addition of 25 L RNase-free water. RNA was stored at Ϫ80°C until further processing.
microRNA Array and Data Analysis
To study the differential miRNA expression in hypertensive patients, we performed miRNA expression profiling of the plasma samples from 13 hypertensive patients and 5 healthy donors using the miRCURY LNA Array (version 11.0) system. RNA samples were labeled with the Exiqon miRCURY Hy3/Hy5 power labeling kit and hybridized on the miRCURY LNA Array (version 11.0) station. Scanning was performed with the Axon GenePix 4000B microarray scanner. GenePix pro version 6.0 was used to read image raw intensity. The intensity of the green signal was calculated after background subtraction, and replicated spots on the same slide were averaged to obtain median intensity. The median normalization method was used to acquire normalized data (foreground minus background divided by median). The median was the 50th percentile of miRNA intensity and was Ͼ50 in all samples after background correction. The threshold value for significance used to define upregulation or downregulation of miRNAs was a fold change Ͼ1.5, with a value of PϽ0.05 calculated by the t test. The miRNAs selected for investigation in our study were further filtered on the basis of expression levels and previously published data.
Real-Time Quantitative Reverse-Transcription Polymerase Chain Reaction
To confirm the findings obtained by analyzing the miRNA profiling, we measured the expression of dysregulated miRNAs using quantitative reverse-transcription (RT) polymerase chain reaction (PCR). The RT reaction used MMLV reverse transcriptase (Epicenter, Madison, WI). Quantitative PCR was performed by an ABI PRISM7500 system (Applied Biosystems, Foster City, CA). The RT primers and the primer sets specific for each miRNA amplification are shown in Table I in the online-only Data Supplement. Selected miRNAs (hcmv-miR-UL112, miR-296 -5p, and let-7e) were further quantified with TaqMan quantitative RT-PCR. The RT stem-loop primers, PCR primers, and probes used are shown in Table II in the online-only Data Supplement.
Fluorescent Reporter Assays
Fluorescent reporter experiments were conducted to confirm that interferon regulatory factor 1 (IRF-1) and major histocompatibility complex class I polypeptide-related chain B (MICB) genes containing the predicted hcmv-miR-UL112 binding site were indeed targets of hcmv-miR-UL112. The enhanced green fluorescent protein (EGFP) cDNA was digested with restriction enzymes to remove it from the pEGFP-N2 vector (Clontech, Palo Alto, CA) and subclone it into pcDNA3.1 (Invitrogen, Carlsbad, CA). The 3Ј UTR fragments from MICB and IRF-1 containing the predicted hcmv-miR-UL112 binding site were amplified from a human brain cDNA library and cloned into pcDNA3.1/EGFP constructs at the BamHI and EcoRI sites. Further information is available in the Methods and Materials section in the online-only Data Supplement.
Western Blot Analysis
Total cell lysates (50 mg) from HEK 293 cells were subjected to SDS-PAGE and electrotransferred to polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA). After blocking in 20 mmol/L Tris-HCl, pH 7.6, containing 150 mmol/L NaCl, 0.1% Tween 20, and 5% (wt/vol) nonfat dry milk, the blots were incubated with the specific rabbit anti-human IRF-1 (Abcam Inc, Cambridge, MA) and anti-GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 4°C. The blots were then incubated with horseradish peroxidaseconjugated secondary antibody (1:3500 dilution; Santa Cruz Biotechnology) for 2 hours while shaking at room temperature. The immunoreactivity was visualized by an enhanced chemiluminescence detection system (Amersham Pharmacia Biotech) according to the manufacturer's instructions. Densitometry plots were analyzed with ImageJ.
Isolation of Circulating Endothelial Cells and Endothelial Progenitor Cells
The expression levels of selected miRNAs (hcmv-miR-UL112, miR-296 -5p, and let-7e) were analyzed in circulating endothelial cells (CECs) and endothelial progenitor cells (EPCs). Blood samples (200 mL) obtained from 3 hypertensive patients and 5 healthy control subjects were used to isolate CECs and EPCs (see the detailed description in the Methods and Materials section in the online-only Data Supplement).
Human Cytomegalovirus Titers
To investigate the association between HCMV infection and essential hypertension, we tested the seropositivity and copy number of HCMV by quantitative PCR in 194 hypertensive patients and 97 control subjects. We extracted HCMV DNA from 200 L separated plasma using the QIAamp DNA Mini kit (Qiagen) according to the manufacturer's protocol. We amplified HCMV DNA by TaqMan real-time PCR with HCMV-specific primers (Table III in the online-only Data Supplement). The 2-step thermocycling procedure consisted of 45 cycles of denaturation at 95°C for 15 seconds and annealing and extension at 60°C for 60 seconds. The PCR product was hybridized to an HCMV-specific, FAM-labeled probe. Serving as a positive control, plasmid DNA containing the HCMV target sequence was used in separate reactions on each TaqMan assay plate. Results were expressed as copies per 1 mL plasma. A negative result was no DNA detection. Any positive PCR result was regarded as positive regardless of the virus load. The seropositivity of EpsteinBarr virus (EBV) and adenovirus was further determined by TaqMan real-time PCR in 194 hypertensive patients and in 97 healthy volunteers. Adenovirus-and EBV-specific primers are listed in Table III in the online-only Data Supplement.
Enzyme-Linked Immunosorbent Assay
Tests for anti-HCMV IgG and IgM antibodies were performed with a commercially available ELISA kit (HCMV Diagnostic Kit, Haitai Biotech Inc, Zhuhai, China) according to the manufacturer's instructions. An ELISA value of Ͻ0.9 U was considered a negative result, and a value of Ն1.1 U was considered a positive result, indicating prior exposure to HCMV (for anti-HCMV IgG) or acute infection with HCMV (for anti-HCMV IgM). A value between 0.9 and 1.1 was considered equivocal.
Statistical Analysis
Values are reported as meanϮSD. The normal distribution of data was tested by the 1-sample Kolmogorov-Smirnov test. The titers of plasma HCMV and the expression levels of hcmv-miR-UL112 were highly skewed; therefore, we used the Mann-Whitney U test to examine differences between groups. Categorical variables were compared by use of the 2 test or Fisher exact test for small samples, and continuous variables were compared by use of the t test. The odds ratios and 95% confidence intervals were calculated to assess the association between the HCMV infection and the risk of hypertension with the multivariate logistic regression model after adjustment for vascular risk factors including age, sex, and body mass index. The relationship between log-transformed titers of HCMV and blood pressure (dependent variable) was determined by multiple linear regression analysis, and the covariates considered were age, sex, body mass index, hyperlipidemia, diabetes mellitus, and history of coronary heart disease. All statistics were performed with SPSS 13.0. A value of PϽ0.05 was considered significant (2 tailed).
Results
Patient Characteristics
The microarray cohort of subjects included 13 hypertensive patients and 5 healthy control subjects. The baseline characteristics of this population are displayed in Table IV in the online-only Data Supplement. In addition to the microarray cohort, we studied a second group composed of 24 hypertensive patients and 22 healthy control subjects for independent validation. Their characteristics are summarized in Table V in the online-only Data Supplement. For further confirmation of hcmv-miR-UL112 expression and investigation of potential associations between HCMV infection and essential hypertension, we conducted a case-control study composed of 194 hypertensive patients and 97 healthy control subjects (Table VI in the online-only Data Supplement).
Expression Profiles of microRNAs in the Plasma of Hypertensive Patients
To determine the differential miRNA expression in hypertensive patients, we profiled plasma miRNA expression of 13 hypertensive patients and 5 healthy donors using the miR-CURY LNA Array (version 11.0) system. The levels of circulating miRNAs differed profoundly between patients and healthy control subjects, as illustrated in the heat map shown in Figure 1 . Of 1700 miRNAs detected on the microarray, 46 miRNAs were found to be differentially expressed in hypertensive patients compared with healthy donors with PϽ0.05; 11 miRNAs were increased and 35 miRNAs were decreased in the patient samples compared with control subjects. Among these 46 miRNAs, 27 were deposited into miRBase. Nine of these 27 miRNAs were upregulated in the hypertensive patient samples: hcmv-miR-UL112, miR-605, miR-623, let-7e, miR-516b, miR-600, kshv-miR-K12-6-3p, miR-602, and miR-1252. Eighteen miRNAs were downregulated: miR-296 -5p, miR-133b, miR-625*, miR-1236, miR-518b, miR-1227, miR-615-5p, miR18b*, miR-1249, miR-324-3p, ebv-miR-BART17-3p, ebvmiR-BART19 -5p, kshv-miR-K12-10a, kshv-miR-K12-10b, miR-486 -5p, miR-30d, miR-664, and miR-634 (Table 1) .
Quantitative Reverse-Transcription Polymerase Chain Reaction Validation of the Profiling Data
To confirm the findings of the miRNA profile, we measured the expression of 20 miRNAs of the 27 dysregulated miRNAs on the basis of their fold changes and P values in the microarray cohort via quantitative RT-PCR. The relative expression of each miRNA in hypertension patients compared with healthy control subjects is shown in Figure 2 . Our results demonstrated an Ϸ2-fold increase in hcmv-miR-UL112 (PϽ0.05), a 1.5-fold increase in let-7e expression (PϽ0.01), and a 2-fold decrease in miR-296 -5p expression (PϽ0.0001) in hypertensive patients. Although kshv-miR-K12-10a demonstrated the lowest expression level in essential hypertensive patients by miRNA profiling (Table 1) , its expression differential between hypertensive patients and healthy volunteers was not statistically significant by our quantitative PCR assay (Pϭ0.11; Figure 2 ).
Next, we focused our studies on 3 miRNAs: hcmv-miR-UL112, let-7e, and miR-296 -5p. We chose hcmv-miR-UL112 because it had the highest expression level in hypertensive patients compared with normal control subjects both in the profiling study and by quantitative PCR (Table 1 and Figure 2 ). let-7e has previously been reported to have a higher expression level in myocardial microvascular endothelial cells, potentially contributory to impaired angiogenesis of type 2 diabetic Goto-Kakizaki rats. 25 We selected miR- 296 -5p because miR-296 can downregulate elevated levels of growth factor receptors on the surface of angiogenic endothelial cells, and inhibition of miR-296 can reduce angiogenesis in tumor xenografts in vivo. 26 
Independent Validation of microRNA Expression
To independently validate the expression of hcmv-miR-UL112, let-7e, and miR-296 -5p, we studied a second set of plasma samples from 24 hypertensive patients and 22 healthy donors. Our results showed an Ϸ2.5-fold increase in hcmvmiR-UL112 expression, a 2-fold increase in let-7e expression, and an Ϸ2.5-fold decrease in miR-296 -5p expression in hypertensive patients compared with healthy control subjects ( Figure 3) Figure I in the online-only Data Supplement). Furthermore, we determined the absolute expression levels of hcmv-miR-UL112, miR-296 -5p, and let-7e in 127 hypertensive patients (of 194) and 67 control subjects (of 97) with available plasma samples using specific miRNA TaqMan assays. The clinical features of these subjects did not significantly differ from the larger set (Table VII in the online-only Data Supplement). The absolute expression levels of hcmvmiR-UL112, miR-296 -5p, and let-7e in hypertensive patients were significantly different from those of controls (fold change, 2.5, 0.5, and 1.7, respectively; all PϽ0.0001), and we found no significant differences in the miRNA expression levels when we compared the patients receiving and those not receiving antihypertensive treatments (Table 2) . Additionally, there were no significant sex differences in the miRNA expression (Table VIII in the online-only Data Supplement).
Interferon Regulatory Factor 1 Is a Direct Target of hcmv-miR-UL112
The target genes of hcmv-miR-UL112 were computationally predicted from optimized intersections and unions of several widely used mammalian target prediction programs, including TargetScan, miRanda, and PicTar. [27] [28] [29] Computational prediction indicated that hcmv-miR-UL112 could target IRF-1 and MICB. MICB was previously shown to be a target of hcmv-miR-UL112. 30 To investigate the direct regulation of IRF-1 and MICB by hcmv-miR-UL112, we cotransfected HEK293 cells with pcDNA3.1-pri-hcmv-miR-UL112 or control plasmid pcDNA3.1 and an EGFP reporter vector that contained either the IRF-1 3Ј UTR or MICB 3Ј UTR carrying the hcmv-miR-UL112 binding site. We demonstrated that EGFP expression was decreased by Ϸ50% in the MICB 3Ј UTR group or by Ϸ60% in the IRF-1 3Ј UTR group when cotransfected with pri-hcmv-miR-UL112 ( Figure 4A and 4B). To further verify the specificity of the miRNA-mediated repression, the hcmv-miR-UL112 binding sites were mutated in the 3Ј UTRs of IRF-1. When the hcmv-miR-UL112 binding site in the IRF-1 3ЈUTR was mutated, hcmv-miR-UL112 could no longer suppress EGFP expression ( Figure  4B ). We also determined the effect of hcmv-miR-UL112 on the IRF-1 protein level in HEK293 cells by Western blot. hcmv-miR-UL112 significantly decreased the IRF-1 expres- Figure 3 . Independent validation of differential expression of microRNA (miRNA) in hypertensive patients. Quantitative reversetranscription polymerase chain reaction for 3 signature miRNAs (hcmv-miR-UL112, miR-296 -5p, and let-7e) in an independent validation set of 24 hypertensive patients and 22 normal control subjects. The relative expression of each miRNA in hypertensive patients compared with healthy control subjects was normalized to U6 expression. Horizontal lines indicate medians. P values were calculated by 2-sided Student t test. sion levels ( Figure 4C ). Taken together, these data suggest that IRF-1 is a direct target of hcmv-miR-UL112.
Cellular Origin of the Circulating microRNAs
To investigate the possible cellular origin of the plasma miRNAs identified in this study, we performed miRNA profiling for peripheral blood mononuclear cells isolated from 10 mL blood from hypertensive patients (nϭ6) and healthy control subjects (nϭ4) using the miRCURY LNA Array (version 11.0) system. miR-296 -5p and hcmvmiRNA-UL112 were not detected in peripheral blood mononuclear cells. Although let-7e was detected in peripheral blood mononuclear cells, there was no significant difference in its expression levels between hypertensive patients and control subjects (1.117 versus 1.098; Pϭ0.93).
We further tested the expression of selected miRNAs in CECs and EPCs. The CEC and EPC counts were not statistically different between patients and control subjects. The expression levels of hcmv-miR-UL112 and let-7e were higher in CECs from hypertensive patients than from control subjects, similar to their expression trends in patient plasma samples. However, the expression patterns of hcmv-miR-UL112 and let-7e in EPCs were opposite to those found in the patients' plasma samples (Table IX in the online-only Data Supplement). The expression pattern of miR-296 -5p in both EPCs and CECs was lower in hypertensive patients compared with healthy control subjects, although not to a statistically significant degree in CECs (Table IX in the online-only Data Supplement). These data indicate that hcmv-miR-UL112 and let-7e may partially originate from CECs.
Detection of Human Cytomegalovirus in Hypertensive Patients
Because the expression of hcmv-miR-UL112 is upregulated in hypertensive patients, we considered the discrepancy of HCMV load in hypertensive patients compared with the control subjects. Using quantitative PCR assays, we detected HCMV DNA in 102 of 194 plasma samples from patients and in 30 of 97 control samples (52.7% versus 30.9%; Pϭ0.0005; Figure 5A ). The HCMV virus titers were significantly higher in hypertensive patients than in control subjects (1870 versus 54 copies per 1 mL plasma; PϽ0.0001; Figure 5B ). The positive rates of anti-HCMV IgG and anti-HCMV IgM were not significantly different between patients and control subjects (94.33% versus 92.78%, Pϭ0.62; 0.59% versus 0%, Pϭ1.0, respectively; Figure 5C ). After adjustment for the confounding hypertension risk factors, we found that HCMV seropositivity and copy number were independently and positively associated with an increased risk of essential hypertension (odds ratio, 2.48 [95% confidence interval, 1.48 to 4.15], Pϭ0.0005; odds ratio, 1.97 [95% confidence interval, 1.58 to 2.46], PϽ0.0001, respectively; Table 3 ). Using a multivariable linear regression model, we found that HCMV virus titers were independently correlated with systolic or diastolic blood pressure (both PϽ0.0001; Table 4 ). In further sensitivity analysis among untreated hypertensive patients, we found that the log-transformed copies of HCMV remained significantly correlated with systolic and diastolic blood pressures (standardized coefficients ␤ϭ0.55 and 0.48, respectively; both PϽ0.0001). Similarly, the correlation between log-transformed expression levels of hcmv-miR-UL112 and systolic or diastolic blood pressure remained significant in patients not receiving antihypertensive therapy (standardized coefficients ␤ϭ0.45 and 0.46, respectively; both PϽ0.0001).
We analyzed the relationship between HCMV virus titers and hcmv-miR-UL112 expression levels in control subjects and hypertensive patients. The results showed that the HCMV virus titers were significantly correlated with hcmv-miR-UL112 expression levels in hypertensive patients (standardized coefficient ␤ϭ0.29; Pϭ0.003) but not in healthy control Interferon regulatory factor 1 (IRF-1) and major histocompatibility complex class I polypeptide-related chain B (MICB) are direct target genes of hcmv-miR-UL112. A, The predicted duplex of hcmv-miR-UL112 (red) and its target site (green) in the 3Ј untranslated region (UTR) of MICB and IRF-1. Schematic representation indicates the mutations made in the IRF-1 3Ј UTRs. B, hcmv-miR-UL112 downregulates MICB and IRF-1 expression in HEK 293 cells when using a firefly enhanced green fluorescent protein (EGFP) reporter assay. Firefly EGFP was normalized to the average intensity of the control reporter. P values were calculated with a paired Student t test. *Pϭ0.001123; **Pϭ0.000028. C, HEK 293 cells were transfected with pri-hcmv-miR-UL112 plasmid, and empty plasmid transfected cells were used as the control. Whole-cell lysates were subjected to Western blot with anti-IRF-1 antibodies. GAPDH expression was used as a loading control. Data are representative results from 3 independent experiments. subjects (␤ϭ0.08; Pϭ0.68; Figure II in the online-only Data Supplement). We further performed subgroup analysis for patients receiving or not receiving antihypertensive therapy and found that the correlation remained significant in patients not receiving antihypertensive therapy (standardized coefficient ␤ϭ0.63; Pϭ0.001), although the correlation was not statistically significant in those receiving antihypertensive therapy (␤ϭ0.20; Pϭ0.08). Our findings indicate an increased HCMV virus titer in hypertensive patients compared with control subjects.
Detection of Epstein-Barr Virus and Adenovirus
To investigate the specificity of the association between HCMV and essential hypertension, we ascertained the seropositivity of EBV and adenovirus in 194 hypertensive patients and 97 control subjects. No statistically significant differences were found in EBV and adenovirus seropositivity between hypertensive patients and healthy control subjects (1.0% versus 0%, Pϭ0.55; 8.8% versus 6.2%, Pϭ0.442, with the Fisher exact test), contributing no evidence of an association between EBV or adenovirus infection and essential hypertension (data not shown).
Discussion
Circulating miRNAs potentially carry disease-specific information owing to inherent genomic alterations or changes in their local environment. 15, 31 In this study, we demonstrated a distinct plasma miRNA expression pattern in hypertensive patients, including 9 miRNAs that were upregulated and 18 miRNAs that were downregulated compared with healthy control subjects. Surprisingly, we found that an HCMV-encoded miRNA, hcmv-miR-UL112, was highly expressed in hypertensive patients. Furthermore, we showed that IRF-1 is a direct target of hcmv-miR-UL112, along with the previously reported MICB. 30 Both IRF-1 and MICB play critical roles in immunologic, inflammatory, and anti-infection responses. 32, 33 Therefore, it is readily plausible that IRF-1 and MICB repression by hcmv-miR-UL112 could be a unifying mechanism evasive of the host response. Additionally, there is increasing evidence that IRF-1 plays significant roles in apoptosis, angiogenesis, neointimal formation, and vascular disease pathogenesis. 34 It can upregulate angiotensin II type 2 receptor, which exerts antiproliferative and proapoptotic actions and regulates blood pressure. 35 It has been reported that targeted disruption of the mouse angiotensin II type 2 receptor gene results in significantly increased blood pressure and increased sensitivity to angiotensin II. 36 Nitric oxide synthase expression and nitric oxide synthesis in macrophages and cardiomyocytes are induced and controlled by IRF-1 in response to inflammation. 37 These critically impor- tant vascular events improve endothelial function and inhibit smooth muscle cell migration. Collectively, these data support a strong relationship between IRF-1 dysregulation and hypertension, suggesting a potential role of hcmv-miR-UL112 in the pathogenesis of hypertension.
To the best of our knowledge, we are the first to report a link between HCMV replication and essential hypertension. After multivariate regression with adjustment for confounding risk factors, HCMV titers remained the strongest predictor of hypertension. Additionally, a recent animal study demonstrated that infection of mice with mouse cytomegalovirus alone can elevate blood pressure, 38 supporting the involvement of HCMV in the pathogenesis of essential hypertension. However, the specific underlying pathophysiological mechanisms linking HCMV with essential hypertension are yet to be defined. Human cytomegalovirus infection exerts an inhibitory effect on endothelial nitric oxide synthase activation, thereby reducing nitric oxide production, activating the stress-response signal P38-MAPK pathway, and upregulating phosphatase and tensin homolog, 21, 22 leading to endothelial dysfunction. 23, 24 Human cytomegalovirus infection stimulates renin and angiotensin II expression in human vascular endothelial cells, 39 enhancing NAD(P)H oxidase activity, and elicits the production of reactive oxygen species. Reactive oxygen species directly cause vasoconstriction through modulation of calcium levels and/or arachidonic acid metabolism. 39, 40 Human cytomegalovirus infection of smooth muscle cells generates reactive oxygen species, which is dependent on cyclooxygenase-2, and activates nuclear factor-B. 41 Nuclear factor-B is associated with endothelial dysfunction and vascular inflammation, as well as vascular smooth muscle cell proliferation. [42] [43] [44] Human cytomegalovirus-infected cells also secrete a number of cytokines (interleukin-6, tumor necrosis factor-␣), chemokines (monocyte chemoattractant protein-1, macrophage inflammatory protein-1␣ and -1␤), growth factors (fibroblast growth factor, platelet-derived growth factor, vascular endothelial growth factor, transforming growth factor-␤), and adhesion molecules (intercellular adhesion molecule, E-adherin), some of which play important roles in smooth muscle and endothelial cell migration and proliferation. 45 These findings may provide a mechanistic basis for the association between HCMV infection and the development of vascular disease and hypertension.
The present study has some limitations. In our initial microarray cohort consisting of 13 hypertensive cases and 5 healthy control subjects, the hypertensive patients were younger and more overweight than control subjects, which might potentially confound our results. However, in the validation cohort consisting of 24 hypertensive patients and 22 healthy control subjects, there were no significant differences in age and body mass index between groups. Additionally, the expression profiles of 3 miRNAs (hcmv-miR-UL112, miR-296 -5p, and let-7e) were similar to those of the initial microarray cohort. In a further case-control study composed of 194 hypertensive patients and 97 healthy control subjects, we confirmed the potential association of HCMV infection with essential hypertension after adjusting for vascular risk factors, including age, sex, and body mass index. Our findings from Chinese hypertensive patients may not be generalizable to other populations because HCMV infection rates may vary across populations. Furthermore, the response to HCMV infection may be different among different ethnic groups. Although the expression trends of the investigated miRNAs in the hypertensive patients are consistent in our studies, we noted high degrees of interpatient differences, which will make it difficult to use the circulating miRNAs as biomarkers for diagnosis or hypertension screening. Whether the assessment of specificity of such miRNA changes is specific for essential or secondary hypertension will need to be the focus of future studies. 
